secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2024-06-25T23:59:59+00:00
Accession:  0001193125-24-167467
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics' WTX-330 Phase 1 shows unconfirmed partial response in melanoma; improved tolerability
--------------------------------------------------------------------------------

- WTX-330 achieved 23-fold higher systemic IL-12 prodrug concentration vs rhIL-12 at 0.024 mg/kg; free IL-12 <1.6% of prodrug (cutoff June 12, 2024).
- Unconfirmed partial response in metastatic melanoma patient who had progressed on adjuvant pembrolizumab; confirmatory scan pending.
- Two MSS CRC patients achieved stable disease (one for 24 weeks); evidence of CD8+ T and NK cell activation in tumor biopsies.
- No Grade 4/5 treatment-related AEs; mild-moderate toxicities (fever, chills, cytopenias) primarily first dose; MTD not established.
- Expansion arms open at 0.024 mg/kg for ICI-resistant or ICI-naive patients; additional data expected Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000119312524167467/0001193125-24-167467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000119312524167467/d857404d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-167467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer